Erythropoietin (EPO) regulates the proliferation and differentiation of erythroid cells by binding to its specific transmembrane receptor, EPOR. Recent studies, however, have shown that the EPOR is additionally present in various cancer cells and EPO induces the proliferation of these cells, suggesting a different function for EPO other than erythropoiesis. Therefore, the purpose of the present study was to examine EPOR expression and the role of EPO in the proliferation and signaling cascades involved in this process, using the rat pancreatic tumor cell line, AR42J. Our results showed that AR42J cells expressed EPOR and EPO significantly enhanced their proliferation. Cell cycle analysis of EPO-treated cells indicated an increased percentage of cells in the S phase, while cell numbers in G0/G1 phase were significantly reduced. Phosphorylation of extracellular regulatory kinase 1/2 (ERK1/2) and c-Jun NH-2 terminal kinase 1/2 (JNK1/2) was rapidly stimulated and sustained after EPO addition. Treatment of cells with MEK inhibitor, PD98059, or JNK inhibitor, SP600125, significantly inhibited EPO-enhanced proliferation and also increased the fraction of cells in G0/G1 phase. Further, the inhibition of JNK using small interference RNA (siRNA) suppressed EPO-enhanced proliferation of AR42J cells. Taken together, our results indicate that AR42J cells express EPOR and that the activation of both ERK1/2 and JNK1/2 by EPO is essential in regulating proliferation and the cell cycle. Thus both appear to play a key role in EPO-enhanced proliferation and suggest that the presence of both is required for EPO-mediated proliferation of AR42J cells.
INTRODUCTION
Erythropoietin (EPO) is a glycoprotein hormone that plays a crucial role in erythropoiesis (39, 65) . Its discovery and preparation through recombinant technology have made it available as a therapeutic drug. Moreover, with pure EPO available, its effect on erythroid cells has been determined to occur via its specific cell surface receptor, EPOR (13) . Recently, however, it has been reported that expression of EPOR is not restricted to hematopoietic cells, but in a variety of other nonhematopoietic cells, such as endothelial, renal, neuronal, and cardiac cells in vitro (6, 58) . Various cell types and tissues of human and animals also express EPO and EPOR (35) , as do several malignant (25, 64, 70) and pediatric tumors (4) . Finally, EPOR expression appears to play a role in tumor progression as suggested by several earlier studies (2, 3, 71) and hence EPO may have a role beyond hematopoiesis.
EPO modulates a host of cellular signal transduction pathways to perform multiple functions in erythroid cells, as well as in other cellular systems (19, 48, 57) . EPOR and EPO signaling is known to activate several intracellular kinase pathways, such as janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT), phosphatidylinositol-3-kinase (PI-3-kinase) (12, 57, 60) , mitogen-activated protein kinases (MAPK) pathways, which include extracellular regulatory kinase 1/2 (ERK1/2), c-Jun NH2 terminal kinase 1/2 (JNK1/2), and p38 MAPK (14, 17, 29, 30, 49-51, 57, 66) . MAPK represent a family of serine-threonine kinases involved in a wide range of cellular responses. Depending on the cellular context, activation of MAPK has been correlated with proliferation, differentiation, cell survival, and apoptosis (24, 40) . Moreover, ERK1/2 is known to be induced by variety of growth factors and hormones, whereas JNK1/2 and p38 MAP kinases are activated by cellular stress, protein synthesis inhibitors, osmotic, heat and chemical shock, and are also thought to be associated with Page 3 of 46 apoptosis (36, 41, 42, 44, 55, 56) . Although JNK1/2 and p38 kinases are often linked to induction of apoptosis and stress, the actual roles of JNK1/2 and p38 are more complicated. It is now clear that both have very diverse roles in the regulation of cell proliferation and survival in some cell types, including erythroid cells (16, 31, 32) . In addition, JNK1/2 has been shown to promote proliferation in response to platelet-derived growth factor and during liver regeneration (34, 61) . Therefore, it is apparent that JNK1/2 also plays a role in mitogenic and growth factor signaling as well. Since the discovery of EPOR expression in cancer cells, there have been reports linking EPO-EPOR signaling in vitro to activate cancer and tumor cell proliferation (1-4, 21, 68, 71) . However, relatively little is known about EPOR-induced signaling in tumor cells.
The aim of the current study was to show the presence of EPORs on rat pancreatic tumor (AR42J) cells, and to determine the role of EPO in proliferation, as well as the mechanism of signal transduction involved in this process. Since the physiological and functional aspect of AR42J cells are similar to freshly isolated pancreatic acinar cells (10, 15) , which we used in our previous studies on MAPK signaling (5), we elected to use this particular pancreatic tumor cell line in our current study.
Materials and Methods

Cell Culture
The AR42J cell line, derived from a rat pancreatic tumor, was obtained from the American Type Culture Collection (Rockville, MD). Cells were grown in 75 cm 2 flasks in 12 ml of medium consisting of Ham's F-12 nutrient medium with 2 mM L-glutamine (Invitrogen Life Technologies, Carlsbad, CA), 1% penicillin and streptomycin, 1.5% sodium bicarbonate, and 10% fetal bovine serum (FBS, Cambrex Bio Science Inc., Walkersville, MD). Flasks were placed in an incubator maintained at 37ºC with 5% CO 2 in air.
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EPO Treatment and Inhibitor Studies
For experiments with MAPK, 60-70% confluent cells were trypsinized, and 1.6 x 10 6 cells plated in 100 mm culture dishes in F-12 nutrient medium containing 10% FBS, and allowed to attach for 12 h. On day 1, the medium was changed to serum-free nutrient medium. On day 2, cells were treated with various concentration of EPO for different lengths of time as shown in the Results section. Specific MEK inhibitor, PD98059, which acts by inhibiting the activation of MAP kinase (subsequently inhibiting phospho ERK activation), and SP600125, a potent, cellpermeable JNK inhibitor (both from Calbiochem Biosciences Inc., La Jolla, CA), were used in MAPK inhibitor studies. Cells were pretreated with 50 HM of PD98059 or 15 HM of SP600125 for 1 h before adding EPO. Equivalent volumes of either medium alone or medium containing DMSO were added to control cultures. The maximum concentration of DMSO in any experiment was 0.1% (v/v), which did not affect the activity or activation of any protein kinase examined.
Human recombinant erythropoietin used in these studies was a generous gift from Centocor (a subsidiary of Johnson & Johnson), Malvern, PA.
Reverse-transcription Polymerase Chain Reaction for EPOR Expression
Cells were plated as described in the previous section and total RNA was extracted using the RNeasy kit according to manufacturer's instructions (Qiagen, Valencia, CA). One microgram of total RNA from each sample was treated with 1 unit of RNase-free deoxyribonuclease I (Amplification Grade, Invitrogen) according to the protocol provided by the manufacturer. First DNA strand synthesis was carried out using 1 Hg DNase-treated RNA and SuperScript II reverse transcriptase (Invitrogen) following the protocol provided by the manufacturer, except that a poly-dT16 primer was used. Mock cDNA preparation lacking reverse transcriptase was done in parallel for control reaction (no RT control). Reaction products (20Hl) PCR products were analyzed by electrophoresis on 1.5% agarose gel. Amplified EPOR was gel purified and confirmed with DNA sequencing analysis by automated sequencing at 3100 Genetic Analyzer (Applied Biosystems, Foster city, CA).
Cell Proliferation Assays
Proliferation of AR42J cells with various doses of EPO, 1-10 mU/ml for 24-96 h, was accomplished by determining the BrdU incorporation during the last 4 h of incubation in the presence of 10 HM BrdU, and measuring colorimetrically using the BrdU ELISA kit, (Roche Diagnostic Corp. Indianapolis, IN), as described earlier (10) . The effect of EPO on the proliferation of AR42J cells was also assessed by a high-sensitivity, commercial colorimetric assay WST-8 cell-counting kit (Dojindo Molecular Technologies, Gaithersburg, MD), using [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium] salt, as reported earlier (5, 10) . In anti-EPOR antibody inhibition studies, AR42J cells were plated and treated with 5mU/ml EPO for 48 h as described previously. Cells were pretreated with 0.02 Hg/ml anti-EPOR antibody (H-194, Sodium azide free antibody purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 1 h before the addition of EPO, and the proliferation was measured with the WST-8 cell-counting kit as described earlier. 
Immunofluorescence Study
Transfection of EPOR siRNA
For EPOR inhibition, a pool of 3 target specific 20-25 nucleotide small interfering RNAs 
Flow Cytometry Analysis
After treatment of AR42J cells with 5 mU/ml EPO alone, MAPK inhibitors (50 HM of PD98059 or 15 HM of SP600125) alone, MAPK inhibitors and then EPO, or vehicle (0.1% DMSO) for 24 h to 96 h, the percentage of cells in the G0/G1, S, and G2/M phase of the cell cycle were determined by utilizing the Guava Cell Cycle reagent kit and performing flow cytometry using the Guava EasyCyte mini system. A total of 7000 ungated events were acquired for each sample. Number of cells, shown under each histogram, represented at least 75% of all the acquired events. The data were further analyzed using CytoSoft software (Guava Technologies, Burlingame, CA), as described earlier (10) .
Western Blot Analysis
Following the treatment with EPO, samples were prepared and Western Blot analysis was performed with antitotal and antiphospho antibodies of ERK-1/2, JNK-1/2, and p38 as described earlier (5, 10) . The extent of phosphorylation was quantitated using a Strom 860 PhophoImager.
For Western blotting studies of EPOR, 25 Hg total proteins from each sample (AR42J cells, K562 cells) were electro-blotted and membrane was blocked with 5% milk in TBS for 1h at room temperature. For EPOR detection rabbit polyclonal anti-EPOR antibody (H-194, Santa
Cruz, CA, 1:1000) was used in 0.5% milk in 1X TBST (TBS containing 0.1% tween-20) for 2 h at room temperature followed by washing and incubation with HRP-conjugated secondary antibody,1:2000 dilution in 0.5% milk in TBST for 1h at room temperature. Visualization of the bands was performed by utilizing SuperSignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL), followed by radiography. Blots were stripped and reprobed with goat polyclonal anti-Actin (C-11). For negative control, antibody, H-194, incubated with excess antigen was used, as described under Immunofliorescence section.
Kinase Assays
Whole cell extracts from stimulated and nonstimulated cells were prepared by suspending cells in 500 Hl of lysis buffer (20mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1mM N-Glycerol phosphate, 1mM Na 3 VO 4 , 1Hg/ml leupeptin) and sonicated on ice. After centrifugation at 14,000xg for 10 min at 4 0 C, supernatant were removed and used for kinase assays. ERK and JNK kinase assays were performed utilizing nonradioactive kinase assay kits (p44/42 MAP kinase assay kit for ERK1/2 activity and 
Results
EPOR Expression in AR42J Cells
We utilized 4 approaches to investigate whether AR42J cells exhibited EPOR on their surfaces. First, we performed immunostaining of AR42J cells grown exponentially in F-12 nutrient medium containing 10% FBS. As shown in Figure 1A , AR42J cells showed a strong immunoreactivity toward EPOR when EPOR antibody was used. In the second approach, the transfection of siRNA for EPOR was done and it reduced this signal considerably indicating reduction of EPOR by this procedure ( Figure 1B ). In the third approach, we performed RT-PCR using RNA from AR42J cells for EPOR. Thirty five cycles of RT-PCR were performed to visualize the EPOR PCR product at the expected size of 363 bp, the results of which are illustrated in Figure 1E . The final product was also confirmed by direct sequencing for EPOR. In the forth approach, Western Blot analysis was performed, which showed a ~66 kDa protein corresponding to EPOR when the total cell lysate of AR42J cells was used for the blot ( Figure   1F 
Effect of EPO on DNA synthesis of AR42J Cells
After ascertaining the presence of EPOR on AR42J cells, we initiated experiments to find the functional significance of EPOR expressed by these cells by incubating them with EPO. In an initial study using the colorimetric BrdU ELISA kit, we determined that 5 mU/ml EPO increased BrdU incorporation into DNA at 48 h compared to the control without EPO. We then undertook a detailed investigation regarding the proliferative pattern of AR42J cells with and without 5 mU/ml EPO over a period from 24h to 96 h. Incubation of cells with 5 mU/ml of EPO induced DNA synthesis, and the level was significantly higher compared to cultures without it (p < 0.05, Figure 2A ). Maximum enhancement of proliferation was seen at 48 h, and it was 3.05 fold above control. At 72h and 96h, BrdU incorporation decreased significantly from the 48h values in both, with and without EPO cultures. However, the difference between EPO added and control cultures were still maintained at these intervals as well (Figure 2A ).
To determine the concentration of EPO that induced maximum proliferation, AR42J cells were incubated for 48 h with different doses of EPO, from 1 mU/ml to 10 mU/ml. With all of the doses of EPO used, proliferation of AR42J cells was elevated above the control (without EPO).
The maximum elevation in proliferation occurred with 5 mU/ml EPO, with a proliferation equivalent of 1.87 fold above the control cultures (p < 0.05) ( Figure 2B ). We used this dose (5 mU/ml) of EPO for all our subsequent studies.
As described previously, we observed the presence of EPOR on AR42J cell surfaces, and to relate this finding with the proliferation of AR42J cells we performed experiments using rabbit polyclonal anti-EPOR antibody, H-194 (sodium azide free). Proliferation in this case was measured by the WST-8 cell-counting kit at 48 h of incubation with or without 5mU/ml of EPO.
When cells were incubated without EPO the proliferation was 1.06 ± 0.01 arbitrary units, which increased by 1.7 fold to 1.82 ± 0.01 arbitrary units when 5mU/ml EPO was also present in the medium. With the pretreatment of AR42J cells with 0.02 Hg/ml of H-194 anti-EPOR antibody alone, the proliferation of these cells was similar to the control, and the value was 1.02 ± 0.02 arbitrary units. When AR42J cells were pretreated with a similar quantity of anti-EPOR and then incubated with EPO, the enhancement of AR42J cells proliferation, as seen with EPO addition, was completely suppressed, the value being 1.16 ± 0.02 arbitrary units, suggesting that EPOR plays a significant role in EPO-enhanced proliferation of AR42J cells.
EPO Activates ERK and JNK in AR42J Cells
The next series of studies were conducted to elucidate EPO-mediated activation of 3 MAPK signals in AR42J cells, namely, ERK1/2, JNK1/2, and p38 MAPK, and these were performed by Western Blot analysis. Figures 3A and 3C illustrate the phosphorylation of ERK1/2 by EPO in AR42J cells. The process was rapid and sustained with a maximum activation in phosphorylation occurring at 5 min compared to the control (increase by 3.06 fold).
However, the amount of total ERK1/2 protein was not affected by EPO treatment at any time point tested ( Figure 3A, top blot) .
Next, we examined the activation of JNK1/2 by EPO in AR42J cells. Immunoblotting the cell lysates with specific antibody to phospho JNK1/2 showed that similar to ERK1/2, JNK1/2 was also stimulated with EPO, although the time course of JNK1/2 activation was markedly different to that of ERK1/2. JNK1/2 phosphorylation was stimulated maximally at 30 min intervals (1.8-fold; Figure 3D ). In contrast, EPO did not activate steady-state levels of total JNK1/2 at any time point examined ( Figure 3B , top blot). We observed a very clear biphasic activation of ERK1/2 and JNK1/2 after EPO treatment. In both cases small, although statistically nonsignificant, second peaks of phosphorylated ERK1/2 and JNK1/2 were seen at the 3h interval ( Figures 3C and 3D) . EPO had no effect on the phosphorylation of p38 MAPK at any time point tested ( Figure 3E ), in spite of the fact that there were reasonably abundant amounts of p38 proteins present in the total cell lysates of EPO-treated and untreated AR42J cells.
In our MAPK studies we found that ERK1/2 and JNK1/2 were induced maximally at 5 and 30 min, respectively. We next examined the subcellular distribution of phosphorylated ERK1/2 and JNK1/2 by immunostaining. AR42J cells were stimulated with 5 mU/ml of EPO for 5 min and 30 min for ERK1/2 and JNK1/2, respectively, as described previously. As shown in Figures 4B and 4D , pERK1/2 and pJNK1/2 fluorescence were significantly higher after 5 min and 30 min of EPO treatment, respectively, compared to untreated cells ( Figures 4A and 4C) .
Kinetics of EPO-stimulated Expression of Elk-1 and c-Jun in AR42J Cells
Since we observed that EPO activates ERK1/2 and JNK1/2 in AR42J cells, it was of interest to determine the functional activities of ERK1/2 and JNK1/2 in these cells after EPO treatment. Cell lysates were prepared from EPO-treated and untreated samples. Figure 5C shows the activity of immunoprecipitated ERK1/2, as determined by Elk-1 phosphorylation. ERK1/2 activity significantly increased 4-fold at 5 min, gradually decreased with time, and attained its lowest activity at 4 h, but still higher than the control cells without EPO (p < 0.05, Figure 5C ).
Next, we examined the protein kinase activity of JNK1/2 at a various time points after EPO stimulation. As depicted in Figure 5D , JNK1/2 activities were elevated upon EPO treatment compared to JNK1/2 activities seen in nonstimulated cells. A marked increase in the activities was detected within 15 min and lasted up to 1 h after EPO treatment, returning to normal levels by 4 h ( Figure 5D) . However, the level of phospho JNK1/2 reached its maximum at 30 min whereas JNK1/2 activity measured by kinase assay reached a maximum at 15 min ( Figure 5D ).
The kinetics of EPO-induced Elk-1 (Fig. 5C ) was parallel to the kinetics of ERK1/2 activation to a very close degree, whereas for JNK1/2, maximum phosphorylation and kinase activity did not show a parallel trend. Both ERK1/2 and JNK1/2 kinase activity did not show any biphasic activation like ERK1/2 and JNK1/2 phosphorylation ( Figures 3C and 3D ). Immunoblot analysis of the same membranes showed that the amounts of immunoprecipitated ERK1/2 and JNK1/2 were similar ( Figures 5A and B, upper blots, respectively) .
MAPK, ERK-1/2 and JNK-1/2, are Involved in EPO-induced AR42J Cell Proliferation
Since ERK and JNK were activated in AR42J cells by EPO, we sought to determine the role of ERK and JNK in EPO-enhanced cell growth and proliferation of these cells using the specific MAPK inhibitors, PD98059 (50 HM, for ERK1/2), and SP600125 (15 HM, for JNK1/2).
The dose of each inhibitor was determined using Western Blots that required to significantly inhibit EPO-induced EKR1/2 and JNK1/2 in these cells at 5 min and 30 min, respectively ( Figures 6C and 6D ). Cell proliferation must proceed by the increase in DNA synthesis, and, therefore, the capability of PD98059 and SP600125 to inhibit the EPO-dependent incorporation of BrdU into DNA was first examined. As shown in Figure 6A , DNA synthesis at 48 h increased 2.3 fold in EPO added cultures and this was inhibited up to the control level when cells were pretreated with 50 HM of PD98059 or 15 HM of SP600125, respectively (p < 0.05). We also observed a similar reduction in the proliferation at 48 h using the WST-8 cell-counting kit. (p < 0.05, Figure 6B ). Addition of these inhibitors alone to cultures did not result in any decrease in cell count below that of the control ( Figure 6A and B) , ruling out the toxicity of these inhibitors on cell proliferation in a normal setting.
Cell Cycle Progression and S-Phase Entry in EPO-treated AR42J Cells
To further verify the proliferative effect of EPO on AR42J cells, cell cycle analysis was performed by flow cytometry. Figure 7A shows that 71.6 ± 1.0% cells were in the G0/G1 phase at 0 hr, with 9.2 ± 0.6% and 12.8 ± 0.6% at the S and G2/M phases, respectively. Following the culture of these cells with 5 mU/ml EPO for 48 h, the percentage of cells in the DNA synthesis phase (S phase) was increased significantly to 33.5 ± 0.5% (p < 0.05), accompanied by a corresponding decrease in the G0/G1 phase of the cell cycle (38.5 ± 0.9%) ( Figure 7D ). In cultures without EPO, cells in the S phase at that interval were significantly less, 15.6 ± 0.5%, with 55.3 ± 0.9% remaining at the G0/G1 phase ( Figure 7C ). At 72 h and 96 h there were no marked differences in the cell cycle distribution at any phase (data not shown). Thus, the observed cell cycle distribution confirmed our results with BrdU incorporation and WST-8 cell counting kit. These results suggest that EPO enhanced the proliferation of AR42J cells by inducing cell cycle progression.
We utilized the inhibitors of ERK (PD98059) and JNK (SP600125) to analyze these results further and examined the percentage of cells distributed in different phases of the cell cycle after treatment with these inhibitors, using flow cytometric analyses previously described.
Both SP600125 and PD98059 abolished the increase in S phase cells 48 h after EPO treatment, and the values were 13.1 ± 0.2% and 11.8 ± 0.2%, respectively, compared to the value of 33.5 ± 0.2% in EPO-alone added cultures (Figures 7E and F) . Thus, activation of both ERK and JNK appears to be critical for the EPO-mediated growth and proliferation of AR42J cells.
Inhibition of EPO-induced Proliferation of AR42J cells by JNK-1/2 RNA Interference
Previous results demonstrate that ERK and JNK are both required for EPO-mediated proliferation of AR42J cells, inhibitor studies also show that inhibition of either ERK or JNK can reduce EPO-dependent proliferation of these cells. To confirm this further, we employed the siRNA approach in conjunction with inhibition of JNK1/2, which should determine the significance of JNK1/2 for the EPO-enhanced proliferation of AR42J cells. The specific knock down of JNK1/2 protein levels was investigated by Western Blotting analysis. As shown in Figure 8C , siJNK transfection effectively decreased the total JNK1 by ~52% and total JNK2 ~97%. Transfection efficiency, using fluorescent oligo as described under "Materials and cells by inhibiting JNK phosphorylation. Nonspecific control siRNA, used as a negative control, had no effect on total JNK proteins (Figure 8 C) . Although the phosphorylated levels of JNK1/2 were increased, the increases were not similar to EPO only treated cells ( Figure 8D ).
Proliferation of nonspecific control siRNA transfected cells were significantly increased above control, as observed in both, CCK8 or BrdU methods ( Figure 8A Santa Cruz through out our study. Our data shows that 5mU/ml EPO stimulates proliferation of AR42J cells. The EPO dose used for this study was established after the dose-response study and 5 mU/ml EPO was found to be optimum for this enhancement in proliferation. In earlier reports, EPO doses from 10 mU/ml to 200 U/ml were used in in vitro studies with different cell systems (3, 22, 26, 54, 62) , which are higher than the dose of 5 mU/ml we employed for AR42J cells. Our time course evaluation of the EPO effect on ERK, as well as JNK activation, showed that ERK1/2 is activated to a maximum extent within 5 min, but JNK1/2 is maximally activated after 30 min. The magnitude and duration of these MAPK activities are very critical for cellsignaling decisions, as transient activation of MAPK triggers proliferation, whereas sustained activation allows differentiation, as shown previously using other cell systems (11, 45, 52). The mechanism of activation of MAPK by EPOR in tumor cells is elusive, but it is likely that the carboxyl-terminal region of the EPOR plays important role in the activation of MAPK and it might occur depending upon either Ras-Raf-1 or PKC activation, as shown previously in human erythroleukemia and EPO-dependent megakaryoblastic cell lines (8, 38, 63, 67) . It might also occur by a Ras-independent mechanism as shown in BaF3 cells (9) . While it has been well documented that ERK, activated by various stimuli, including growth factors, is implicated in proliferation, and JNK is involved in stress-induced apoptosis (5, 7, 41, 42, 44, 55, 58) , an accumulating body of evidence has recently suggested that JNK plays a key role in cell survival and proliferation for a variety of cell types (16, 31, 32, 44, 53) . Other studies have also suggested 
